AIDS TREATMENT NEWS Issue #189, December 17, 1993
Denny Smith
People who face ongoing depression or anxiety often find therapy or counseling valuable, and many community-based agencies can offer such therapy to people with HIV. Sometimes, however, a counselor or social worker will suggest a consultation with an HIV-experienced psychiatrist, who can offer pharmacological treatment when helpful.
We interviewed J. Kevin Rist, M.D., to gain some insight into the psychiatric facets of HIV disease. Dr. Rist is an attending psychiatrist in the HIV Services department at St. Mary's Hospital and Medical Center in San Francisco. He also cares for a number of HIV-infected clients in his private practice.
* * *
DS: Is your treatment approach to HIV-infected patients significantly different from your treatment for other patients?
KR: It's not very different from treating other patients who are also dealing concurrently with physical illness. For example, physical illness often means that these individuals are in fragile health and are already on a number of nonpsychiatric drugs. So you have to be aware of drug side effects, and interactions. Most of all, people come to us hurting or suffering, or needing something. It's not always comfortable for human beings to need something from, or to be dependent on, someone else. It's a vulnerable situation. I think it's particularly common for patients facing a life- threatening illness to get depressed, to feel anxious, to have sleep disturbances.
DS: What would you say to primary care physicians who are not accustomed to assessing or treating psychiatric symptoms in their patients?
KR: Physicians in other specialties are often very preoccupied, quite legitimately, with other things. But I think it's generally true that depression and anxiety are underdiagnosed in people with HIV, and if an internist can gain familiarity with treating psychiatric symptoms in their patients, that's good.
Unfortunately, what I see a lot of, in patients referred to me by primary care providers, is the misprescription of benzodiazepine drugs: lorazepam (Ativan), diazepam (Valium), alprazolam (Xanax), flurazepam (Dalmane), temazepam (Restoril), triazolam (Halcion). I think that people perceive those drugs to be safe, but actually they are very addictive. You quickly build up a tolerance for them, and need more to obtain a therapeutic effect. Then both the patient and the doctor may find themselves in a quiet struggle over the issue, with the patient feeling guilty for wanting more and the physician feeling guilty for prescribing more, and the whole issue unnecessarily becoming an interpersonal one.
If, instead, the physician were a little more savvy, and noticed some anxiety symptoms or trouble sleeping at night, he or she might ask more questions and realize these are really manifestations of depression, and treat them with the proper antidepressant medication, or refer them to someone who will treat accordingly. That way the patient will get better symptomatic relief, be more motivated to trust the doctor and work with the doctor, and avoid getting into a self-destructive cycle of being dependent on something that only their doctor can give them.
DS: So the benzodiazepines are not antidepressants?
KR: No, they are approved and marketed for various other indications, such as immediate anxiety. They are not appropriate for long-term therapy. Using them to treat depression is a little like treating a serious fever with aspirin, without delving further into the underlying cause of the fever. If someone is extremely troubled, I may offer a benzodiazepine like lorazepam along with an antidepressant like imipramine, and taper off the lorazepam as the antidepressant takes effect, which can take several weeks. I've seen patients who were actually on two different benzodiazepines-one for anxiety and one for sleeplessness. That kind of combination can cause cognitive impairment and even be dangerous, especially when mixed with alcohol. So rather than treating every symptom with a different medicine, I like to see people on simplified, clean regimens of psychiatric medications.
DS: On a related note, a lot of people with HIV have a history of recreational drug use, and a lot of people with a history of chemical dependency are now HIV-infected. And yet we are perhaps finally emerging from the Reagan/Bush approach to drugs, now considered essentially a nonproductive social policy. What is a productive attitude in the 90s?
KR: I want patients to feel safe to talk about drug use. If someone is now using drugs, I talk to them about what they want to do with their life. You can be clear that you don't approve of something that's not in their best interest, and still maintain a mutually respected position with each other. You can express disapproval of a behavior rather than a person. With a punitive or a "just say no" approach, you're just going to lose the patient; you have no chance of helping someone who leaves your care.
So the first question I ask on this issue is "Are drugs or alcohol a problem for you--have they ever caused you any negative consequences?" If the answer is "No," and I don't perceive any problems, like elevated liver enzymes, then the issue is set aside. If the answer is "Yes," or "Sometimes," then I ask "Why do you continue using them--would you like me to help you with this?" It is not productive to be judgmental. If you want someone to be capable directing their own life, then on some level you have to be comfortable with them directing their own care.
DS: Which psychiatric drugs are appropriate in the context of HIV care?
KR: Except for the benzodiazepines, I'll rely on the traditional antidepressants, such as the tricyclics-- amitriptyline (Elavil), imipramine (Tofranil), nortriptyline (Pamelor)--as well as the newer generation, such as fluoxetine (Prozac) and sertraline (Zoloft). Although these are specifically indicated for treating depression, by extension they can also relieve anxiety and problems sleeping.
I think that low-dose antipsychotics, such as perphenazine (Trilofon), are good for treating overwhelming anxiety, or psychotic depression, especially in patients who have not responded to the other drugs.
DS: How do you distinguish depression and anxiety from the early symptoms of dementia? [For a larger discussion of cognitive and motor deficits, see AIDS TREATMENT NEWS issue number 171, March 19,1993.]
KR: It's important to remember that most cognitive impairment is not dementia. First, of course, you are obligated to look for any life-threatening opportunistic diseases, using whatever neurologic tests are appropriate--MRI [magnetic resonance imaging] or LP [lumbar puncture], etc. Then you ask if drugs are a factor, either prescribed or recreational drugs. Then you try to rule out psychiatric symptoms, such as depression. HIV-associated dementia is the remaining diagnosis to make in the situation.
DS: For a number of years, the dominant mental health model of "how to be" a person with AIDS was basically a death and dying model. It was not a monolithic model, but the aggressive treatment approach largely took a back seat to the acceptance of death. There are still health care providers who routinely refer to HIV infection as a terminal illness, rather than a life-threatening disease. How is it possible to view HIV as something to survive, or at least to live with?
KR: Having HIV now should be seen as dealing with a chronic illness. I have at least two patients who are long-term survivors. Neither of them ever expected to remain healthy or even to be around this long, and they have had to find the strength to survive the losses all around them. One of them was once told that he had only six months left to live. That was ten years ago, and people like him now present the psychiatric community with a whole new set of issues, including how to live when you didn't expect to, how not to die.
931217
ATN18901
Copyright © 1993 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .